PHIOW Projected Dividend Yield
Phio Pharmaceuticals Corp ( NASDAQ : PHIOW )Phio Pharmaceuticals is a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. Co. is focused on its proprietary INTASYL™ platform with utility in immune cells and/or the tumor micro-environment. Co. has two product candidates that are being developed for use in Adoptive Cell Transfer, PH-762 and PH-804. Co.'s primary pipeline compound, PH-762, targets the checkpoint protein PD-1, a checkpoint protein on immune cells. Co.'s second pipeline compound, PH-804, targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. 20 YEAR PERFORMANCE RESULTS |
PHIOW Dividend History Detail PHIOW Dividend News PHIOW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |